Cargando…

Use of real-world evidence data to evaluate the comparative effectiveness of second-line type 2 diabetes medications on chronic kidney disease

Chronic kidney disease (CKD) is a common complication of type 2 diabetes mellitus (T2DM). Approximately-one-third of patients with T2DM also have CKD. In clinical trial studies, several anti-diabetic medications (ADM) show evidence of preventing the progression of CKD. Biguanides (e.g., metformin) a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Yu, Ghamsari, Farhad, Lu, Alice, Yu, Jingzhi, Zhao, Lihui, Kho, Abel N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816064/ https://www.ncbi.nlm.nih.gov/pubmed/36620756 http://dx.doi.org/10.1016/j.jcte.2022.100309

Ejemplares similares

Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020)

Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2021)

Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence
por: Cuker, Adam, et al.
Publicado: (2023)

Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trial
por: Deng, Yihong, et al.
Publicado: (2023)

Real World Evidence in Medical Cannabis Research
por: Banerjee, Rishi, et al.
Publicado: (2021)

Glycemic Outcomes of Second-Line Diabetes Drug Choice in a Real-World Population
por: Wallia, Amisha, et al.
Publicado: (2021)

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
por: Dai, Wei Fang, et al.
Publicado: (2020)

Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma
por: Rodríguez-Cid, Jeronimo Rafael, et al.
Publicado: (2020)

Direct Cost of Parkinson's Disease: A Real-World Data Study of Second-Line Therapies
por: Gomez-Inhiesto, Elisa, et al.
Publicado: (2020)

The value of real world evidence: The case of medical cannabis
por: Schlag, Anne Katrin, et al.
Publicado: (2022)

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
por: Chen, You-Yi, et al.
Publicado: (2021)

Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium
por: Schinzari, Giovanni, et al.
Publicado: (2018)

A real-world experience of second-line nivolumab in mesothelioma patients during the COVID-19 pandemic
por: Church, Matt, et al.
Publicado: (2021)

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
por: King, Gentry, et al.
Publicado: (2022)

Editorial: Real-World Evidence of Pediatric Exposure to Psychopharmacologic Medications
por: Zito, Julie M., et al.
Publicado: (2022)

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
por: Wang, Chin‐Chou, et al.
Publicado: (2021)

Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies
por: Heng, Daniel Y., et al.
Publicado: (2014)

Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
por: Koutsoukos, Konstantinos, et al.
Publicado: (2017)

Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
por: Barzi, Afsaneh, et al.
Publicado: (2019)

Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Real‐world outcomes among patients with advanced or metastatic biliary tract cancers initiating second‐line treatment
por: Cosgrove, David P., et al.
Publicado: (2022)

Real-World Evidence for Equality
por: Johnson, C. Erwin, et al.
Publicado: (2021)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

Editorial: Real-world data and real-world evidence in hematologic malignancies
por: Malagola, Michele, et al.
Publicado: (2023)

Clinically meaningful benefit: real world use compared against the American and European guidelines
por: Dreicer, Jessica J., et al.
Publicado: (2017)

Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations
por: Jun, Soojin, et al.
Publicado: (2023)

Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease
por: Folkerts, Kerstin, et al.
Publicado: (2022)

Informing real-world practice with real-world evidence: the value of PRECIS-2
por: Neta, Gila, et al.
Publicado: (2018)

Proceed with Caution When Using Real World Data and Real World Evidence
por: Kim, Hun-Sung, et al.
Publicado: (2019)

4505 Implementation of Real-World Data and Real-World Evidence in Clinical Studies
por: Pham, Jessica, et al.
Publicado: (2020)

Real world evidence (RWE) – a disruptive innovation or the quiet evolution of medical evidence generation?
por: Khosla, Sajan, et al.
Publicado: (2018)

MEDICAL HISTORY OF THE SECOND WORLD WAR: SURGERY
Publicado: (1954)

Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance
por: Magnani, Christopher J., et al.
Publicado: (2020)

The Missing Reality of Real Life in Real‐World Evidence
por: Okun, Sally
Publicado: (2019)

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
por: Rittberg, Rebekah, et al.
Publicado: (2023)

Examining the Use of Real‐World Evidence in the Regulatory Process
por: Beaulieu‐Jones, Brett K., et al.
Publicado: (2019)

Real-World Evidence to Assess Medication Safety or Effectiveness in Children: Systematic Review
por: Lasky, Tamar, et al.
Publicado: (2020)

Advancing the Real-World Evidence for Medical Devices through Coordinated Registry Networks
por: Sedrakyan, Art, et al.
Publicado: (2022)

Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group
por: Zheng, Yu-Xin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d07ou8vfg39o7u82hpcsu1gqa7